ICICI Prudential Nifty Pharma Index IDCW Reinvest Direct Plan
SIP amount
Min. ₹1,000
Lumpsum amount
Min. ₹1,000

ICICI Prudential Nifty Pharma Index IDCW Reinvest Direct Plan

NAV
₹17.3545
+0.83%
(20 Oct)
AUM
88 Cr
TER
0.37%
Risk
Very High Risk
Insights
Total Expense Ratio (TER) is in the bottom 25% of comparable funds
Net Asset Value (NAV) is above its 200 days moving average
In beta. Send feedback here.
Compare with other fund
1Y
+9.4%
+9.4%
+9.4%
-4.0%
-4.9%
3Y
+29.6%
+29.6%
+29.6%
NA
+26.2%
5Y
NA
NA
NA
NA
NA
ALL
+29.6%
+29.6%
+29.6%
+21.3%
+17.9%
VOL
16.8%
16.8%
16.8%
14.6%
20.4%
TER
0.4%
0.4%
0.4%
0.4%
0.5%
AUM
₹167 Cr
₹167 Cr
₹167 Cr
₹88 Cr
₹248 Cr
INFO
1.76
1.76
1.76
1.46
0.87
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
ICICI Pru Nifty Pharma Index IDCW Reinvest (DR)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 30th Sep
Top holdings
Sun Pharmaceuticals Industries Ltd
21.6%
Cipla Ltd
10.9%
Dr Reddy's Laboratories Ltd
9.6%
Divi's Laboratories Ltd
9.3%
Lupin Ltd
5.9%
Torrent Pharmaceuticals Ltd
4.8%
Laurus Labs Ltd
4.2%
Alkem Laboratories Ltd
3.9%
Aurobindo Pharma Ltd
3.9%
Glenmark Pharmaceuticals Ltd
3.8%
Top industry exposure
Healthcare
99.9%
Other information
Minimum SIP
₹1,000
Minimum lumpsum
₹1,000
Additional lumpsum
₹1,000
Portfolio turnover
45%
Lock-in period
-
Exit load
No exit load
Fund objective
The objective of the Scheme is to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index. However, there is no assurance or guarantee that the investment objective of the scheme shall be achieved.
Fund manager(s)
Nishit Patel
Ashwini Shinde

FAQs